BGB-C354
- Generic Name
- BGB-C354
A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 62
- Registration Number
- NCT06422520
- Locations
- 🇨🇳
Liaoning Cancer Hospital and Institute, Shenyang, Liaoning, China
🇺🇸Florida Cancer Specialist Research Institute Lake Nona, Orlando, Florida, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath